首页膀胱肿瘤诊断证据详情

Unmet informational and supportive care needs of patients with muscle invasive bladder cancer: A systematic review of the evidence

原文: 2018 年 发布于 Eur Urol 6 卷 第 7 期 705-726 浏览量:166次

作者: Paterson C. Jensen B. T. Jensen J. B. Nabi G.

作者单位: Program for Personalized Cancer Care NorthShore University HealthSystem Evanston Illinois USA. Midwestern University Chicago College of Osteopathic Medicine Downers Grove Illinois. Department of Surgery NorthShore University HealthSystem Evanston Illinois USA. Department of Surgery University of Chicago Pritzker School of Medicine Chicago Illinois USA.

归属分类: 膀胱肿瘤诊断证据

DOI: 10.3390/cancers15030709

关键词: Disease Progression Humans Prognosis Risk Factors Tumor Suppressor Protein p53/*metabolism Urinary Bladder Neoplasms/*metabolism/*pathology Meta-analysis Non-muscle invasive bladder cancer Progression Stage T1 p53

文献简介

Objective: The objective of this study was to perform a systematic review and meta-analysis to evaluate the two most commonly used chemotherapy regimens gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, doxorubicin/adriamycin, and cisplatin (MVAC) regimens for muscle-invasive bladder cancer (MIBC) patients. Methods: We searched for all studies investigating GC and MVAC for MIBC patients in PubMed, Web of Knowledge, and the Cochrane Central Search Library. A systematic review and meta-analysis were performed. Results: Our searches identified 13 studies among 2174 patients. In the meta-analysis, the pathological complete response to GC regimens was superior to MVAC regimens. No significant difference in pathological partial response was found between the two groups. GC regimens were associated with a significant decrease risk in Grade 3-4 neutropenia, mucositis, and febrile neutropenia, but a significant increase risk in Grade 3-4 thrombocytopenia. There was no significant difference in overall survival (OS), disease-specific survival (DSS) and disease-free survival (DFS) when compared GC regimens to MVAC regimens. Conclusions: GC regimens significantly improved pathological complete response compared to MVAC regimens. GC regimens were associated with a significant decrease risk in Grade 3-4 neutropenia, mucositis, and febrile neutropenia, but a significant increase risk in Grade 3-4 thrombocytopenia. There was no significant difference in OS, DSS, and DFS when compared the two regimens.

热门文献